Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036572 (seizures)
 80,221 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Each year, the Shils Fund recognizes outstanding activities that help improve oral health. The program is named in memory of Dr. Edward B. Shils, who led the Dental Manufacturers of America and Dental Dealers of America for more than 50 years. A 2010 Shils Award will be given to an innovative school health initiative called Fit For Schools Program (FFSP) in the Philippines. Such recognition in the US indicates the lessons that can be learned from a program initially tailored for another country. Health in a highly industrialized nation can be enhanced by heeding the FFSP principles used to craft an effective health promotion initiative. This evidence-based intervention is not exclusively an oral health initiative; it is an integration with other evidence-based health interventions and models a sustainable public-private partnership to advance positive health outcomes in socially responsible entrepreneurial ways. As the editor of this column in Compendium, I wish to applaud both leaders of FFSP: Dr. Habib Benzian and Dr. Bella Monse. The following article was written by the senior advisor, Dr. Benzian, who modestly refers to the program's receipt of another award from the World Bank, the United Nations Development Program, and the World Health Organization in 2009. To my knowledge, the presentation of that award was the first time a health promotion project led by dentists has ever received such high-level global recognition and was one of three projects so recognized for innovative solutions to global health in that year.
 ...
PMID:Revitalizing school health programs worldwide. 2096 Sep 87

Frederic Gibbs' (1903-1992) long research career was devoted to the understanding and treatment of epileptic phenomena and closely associated with the development of electroencephalography (EEG). After medical school, he joined the Harvard Neurological Unit at Boston City Hospital directed by Stanley Cobb. In the early 1930s, Gibbs developed a thermoelectric blood flow probe and, with William Lennox, proved in animals and humans that a seizure increases cerebral blood flow. By 1934, Gibbs became a pioneer in the field of EEG while working at Harvard with Hallowell Davis and Lennox, and was the first to convincingly record and report EEG findings in epilepsy and states of altered consciousness. Several years later, Gibbs and Lennox were the first to recommend cerebral excisions in several patients with uncontrolled epilepsy based on EEG. Moving to the University of Illinois at Chicago in 1944, Gibbs founded a consultation clinic for epilepsy, performed the first EEG depth recordings using pneumoencephalography-guided stereotaxy, and noted that sleep EEGs in patients with psychomotor seizures frequently disclosed temporal epileptic patterns. Gibbs convinced Percival Bailey to collaborate on patients with refractory temporal lobe psychomotor seizures without tumors. In 1947, the first nonlesional temporal lobe excisions based on EEG localization were performed in these patients, and, by 1948, anterior temporal lobectomy had become their procedure of choice. Gibbs and Lennox received the coveted Lasker Award among other honors as pioneers in establishing the modern era of epilepsy diagnosis and treatment.
 ...
PMID:Frederic Gibbs and his contributions to epilepsy surgery and electroencephalography. 2190 65

In recent years, there has been a growing appreciation by regulatory authorities that cannabis-based medicines can play a useful role in disease therapy. Although often conflagrated by proponents of recreational use, the legislative rescheduling of cannabis-derived compounds, such as cannabidiol (CBD), has been associated with the steady increase in the pursuit of use of medicinal cannabis. One key driver in this interest has been the scientific demonstration of efficacy and safety of CBD in randomised, placebo-controlled clinical trials in children and young adults with difficult-to-treat epilepsies, which has encouraged increasing numbers of human trials of CBD for other indications and in other populations. The introduction of CBD as the medicine Epidiolex in the United States (in 2018) and as Epidyolex in the European Union (in 2019) as the first cannabis-derived therapeutic for the treatment of seizures was underpinned by preclinical research performed at the University of Reading. This work was awarded the British Pharmacological Society Sir James Black Award for Contributions to Drug Discovery 2019 and is discussed in the following review article.
 ...
PMID:Development of cannabidiol as a treatment for severe childhood epilepsies. 3298 48